IP Library Granted Patent US 7,872,105
Granted Patent B2
US 7,872,105 · App. 11/440,137 · Granted Jan 18, 2011

Anticarcinoma antibodies and uses thereof

Assignees: National Research Council of Canada; Ottawa Hospital Research Institute
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,872,105
App. No.
11/440,137
Granted
Jan 18, 2011
Kind
B2
Abstract

A novel single domain antibody AFAI and fragments thereof which has specific affinity for binding to carcinoma, and especially lung carcinoma. This antibody, and portions thereof, can be used, inter alia in the diagnosis and treatment of carcinoma.

Claims (20)

1. An isolated single V H domain antibody comprising complementarily determining region (CDR) 1 sequence KNLMG SEQ ID NO.4, CDR2 sequence TISGSGGTNYASSVEG SEQ ID NO.6, and CDR3 sequence AFAI SEQ ID NO.3, and wherein the isolated single domain antibody binds to non-small cell lung carcinoma.

2. A conjugate comprising the isolated single V H domain antibody of claim 1 and a cargo substance.

3. A kit comprising:

the conjugate of claim 2 ; and

instructions for use of the conjugate.

4. An oligomer comprising the isolated single V H domain antibody of claim 1 .

5. The oligomer of claim 4 wherein subunits are linked using at least one of: a peptide linker, a self assembly molecule oligomerization domain, and chemical coupling.

6. The oligomer of claim 4 comprising at least two different subunits.

7. The oligomer of claim 4 comprising at least two identical subunits.

8. The oligomer of claim 6 wherein at least one subunit is an antibody having a different specificity than the polypeptide of SEQ ID NO:1.

9. The oligomer of claim 6 wherein at least one subunit has an enzymatic function.

10. The oligomer of claim 6 wherein at least one subunit comprises a cargo substance.

11. The isolated single V H domain antibody of claim 1 , wherein the sequence comprises SEQ ID NO.1.

12. The single V H domain antibody of claim 1 , wherein the CDR appear in the order listed, and wherein there is a gap of 12 to 16 amino acids between KNLMG SEQ ID NO.4 and TISGSGGTNYASSVEG SEQ ID NO.6, 30 to 34 amino acids between TISGSGGTNYASSVEG SEQ ID NO.6 and AFAI SEQ ID NO.3, and 46 to 66 amino acids between KNLMG SEQ ID NO.4 and AFAI SEQ ID NO.3.

13. The single V H domain antibody of claim 1 , comprising the sequence:

DVQLQASGGGX 1 VQPGGSLRLSCAAHDPIFDKNLMGWX 2 RQAPGKX 3 X 4 EX 5 VATISG SGGTNYASSVEGRFTISRDNAKKTVYLQMNDLKPEDTAVYYCNSAFAIX 6 GQGTQVT VSS SEQ ID NO.5

wherein X 1 , is: V, S, D, L, F, W, or T; X 2 is: G, F, Y, V, I, H, or L; X 3 is: Q, G, E, D, L, R, or K; X 4 is: R, C, Q, L, I, P, or K; X 5 is: Y, T, A, W, F, S, or L; X 6 is: W, R, E, A, G, V, or K.

14. The single V H domain antibody of claim 1 , wherein the sequence comprises SEQ ID NO:2.

15. The oligomer of claim 4 , wherein the isolated single V H domain antibody comprises the sequence of SEQ ID NO:1.

16. The oligomer of claim 4 , wherein the isolated single V H domain antibody comprises the sequence of SEQ ID NO:2.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 29, 2010
From: MACKENZIE, COLIN ROGER; ZHANG, JIANBING; NGUYEN, THANH-DUNG; LI, QINGGANG
To: NATIONAL RESEARCH COUNCIL OF CANADA
Reel/Frame 025426/0442 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 29, 2010
From: MAI, KIEN TRUNG
To: OTTAWA HOSPITAL RESEARCH INSTITUTE
Reel/Frame 025427/0233 →
CHANGE OF NAME Recorded Nov 19, 2010
From: OTTAWA HEALTH RESEARCH INSTITUTE/L'INSTITUT DE RECHERCHE EN SANTE D'OTTAWA
To: OTTAWA HOSPITAL RESEARCH INSTITUTE/INSTITUTE DE RECHERCHE DE L'HOPITAL D'OTTAWA
Reel/Frame 025411/0331 →
Continuity (3)
Continuation In Part PCTCA200400148800 · Aug 17, 2004
Continuation In Part 1054752800
Related Publication 20060286113A1 · Dec 21, 2006